Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...
Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback